CSL LTD SP/ADR - CSLLY STOCK NEWS

CSL Limited (ASX: CSL) has outlined a set of ambitious targets aimed at reducing carbon emissions as part of its sustainability strategy. By 2030, CSL plans to cut 40% of its absolute Scope 1 & 2 emissions compared to average annual emissions from FY19-21. Additionally, the company aims to have suppliers responsible for 67% of Scope 3 emissions commit to similar reduction targets. Key strategies for emissions reduction include increasing energy efficiency and switching to renewable power sources.

CSL has announced a move to unify its brand by incorporating its name across all business units. This change aims to strengthen its identity as a single entity while maintaining the distinctiveness of CSL Behring and CSL Plasma. Seqirus will be rebranded to CSL Seqirus, and the recently acquired Vifor Pharma will be known as CSL Vifor. CEO Paul Perreault highlighted that this rebranding aligns with CSL's purpose-driven strategies and values, emphasizing patient focus and innovation. The company continues to serve over 100 countries with lifesaving therapies.

CSL Plasma has launched the Rika Plasma Donation System at its Aurora, Colorado location, marking the first of over 300 U.S. centers to adopt this advanced technology. The Rika system aims to reduce plasma collection time by approximately 30%, enhancing the overall donor experience. The design minimizes the volume of blood outside the donor's body, resulting in a more comfortable donation. The rollout is part of CSL Plasma's commitment to improve operational efficiency and meet the increasing demand for plasma-derived therapies.

CSL Limited has received all regulatory approvals for the acquisition of Vifor Pharma AG, with settlement set for 9 August 2022. CSL expects to acquire over 97% of Vifor shares post-settlement and plans to delist Vifor. Hervé Gisserot will become General Manager of Vifor upon settlement. CEO Paul Perreault emphasized the acquisition's strategic importance, enhancing CSL's capabilities in rare disease treatment. Vifor's CEO Abbas Hussain expressed confidence in the future within CSL's global framework, allowing for accelerated growth and product launches.

CSL Limited (ASX: CSL; USOTC: CSLLY) announced a further postponement of its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. The settlement, originally set for July 22, 2022, is now extended until September 30, 2022, due to unmet offer conditions regarding merger clearances. This delay follows an initial postponement announced on March 28, 2022. Additionally, CSL has filed for the cancellation of the remaining publicly held Vifor shares.

Seqirus, part of CSL Limited, has commenced shipping its innovative influenza vaccine portfolio for the 2022/23 U.S. season. This includes the first cell-based quadrivalent vaccine, FLUCELVAX®, now available for ages six months and older, and the adjuvanted quadrivalent vaccine FLUAD®, which the CDC recommends for adults aged 65 and older. Seqirus aims to supply over 55 million doses, highlighting the importance of vaccination amidst potential flu resurgence. The CDC notes significant flu-related deaths and hospitalizations, emphasizing vaccination as crucial for public health.

On June 22, 2022, the CDC's ACIP recommended FLUAD® QUADRIVALENT as a preferential flu vaccine for adults 65 and older, emphasizing its clinical benefits over standard vaccines. This recommendation is based on extensive studies showing FLUAD's efficacy in enhancing immune responses, particularly in older populations at higher risk for influenza-related complications. With over 225 million doses distributed globally since its approval, FLUAD aims to protect vulnerable groups from severe illness during the upcoming influenza season.

CSL Behring and photographer Rankin unveil 'Portraits of Progress' in New York City, marking their first in-person exhibit in three years. This multimedia campaign showcases the evolution of hemophilia treatment, from the 1940s to modern gene therapy research. Opening on June 11, 2022, the exhibit features portraits and personal narratives from individuals with hemophilia, highlighting advances in treatment and community hopes for the future. CSL Behring aims to raise awareness of hemophilia and its impact, reinforcing its commitment to innovation in healthcare.

Seqirus, a global influenza vaccine leader under CSL Limited, has completed a $156 million expansion of its manufacturing facility in Holly Springs, N.C. The new line for pre-filled syringes has received FDA approval and will enhance the production of FLUCELVAX® QUADRIVALENT, the only cell-based quadrivalent influenza vaccine in the U.S. The expansion supports over 80 skilled jobs and increases capacity for seasonal vaccines and pandemic readiness. Seqirus aims to respond better to the growing demand for differentiated influenza vaccines.